Clinical Trial

Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

Name: Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma — clinical trial record (NCT06764251)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.

Trial Details

NCT Number	NCT06764251
Lead Sponsor	Liaoning Cancer Hospital & Institute
Conditions	Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment	20 participants
Start Date	2024-12-30
Primary Completion	2027-12-31 (estimated)
Study Completion	2028-03-31 (estimated)
Updated on ClinicalTrials.gov	2025-01-08